Johnson & Johnson Stock

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-05-02 pm EDT 5-day change 1st Jan Change
149.9 USD -0.83% Intraday chart for Johnson & Johnson +0.94% -4.35%
Sales 2024 * 88.37B Sales 2025 * 90.78B Capitalization 364B
Net income 2024 * 22.04B Net income 2025 * 22.98B EV / Sales 2024 * 4.04 x
Net cash position 2024 * 7B Net cash position 2025 * 21.07B EV / Sales 2025 * 3.78 x
P/E ratio 2024 *
16.8 x
P/E ratio 2025 *
15.9 x
Employees 131,900
Yield 2024 *
3.19%
Yield 2025 *
3.33%
Free-Float 76.37%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Johnson & Johnson

1 day-0.83%
1 week+0.94%
Current month+3.69%
1 month-4.98%
3 months-5.33%
6 months+0.83%
Current year-4.35%
More quotes
1 week
144.53
Extreme 144.53
152.33
1 month
143.13
Extreme 143.13
158.05
Current year
143.13
Extreme 143.13
163.58
1 year
143.13
Extreme 143.13
175.97
3 years
143.13
Extreme 143.13
186.69
5 years
109.16
Extreme 109.16
186.69
10 years
81.79
Extreme 81.79
186.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 88-12-31
Director of Finance/CFO 57 97-12-31
Chief Tech/Sci/R&D Officer 58 19-11-04
Members of the board TitleAgeSince
Director/Board Member 70 19-04-24
Director/Board Member 72 14-06-18
Director/Board Member 70 09-10-21
More insiders
Date Price Change Volume
24-05-02 149.9 -0.83% 8,303,877
24-05-01 151.2 +4.56% 14,473,711
24-04-30 144.6 -1.52% 8,817,719
24-04-29 146.8 +0.47% 6,461,588
24-04-26 146.1 -0.46% 6,182,982

Delayed Quote Nyse, May 02, 2024 at 04:00 pm EDT

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
151.2 USD
Average target price
173.3 USD
Spread / Average Target
+14.61%
Consensus